Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients

Giuseppe Derosa, Pamela Maffioli, Sibilla A T Salvadeo, Ilaria Ferrari, Alessia Gravina, Roberto Mereu, Ilaria Palumbo, Elena Fogari, Angela D'Angelo, Arrigo F G Cicero

Research output: Contribution to journalArticlepeer-review

Abstract

The aim of this study is to compare the effects of candesartan and olmesartan on insulin sensitivity-related parameters, before and after antihypertensive therapy. After a 4-week washout placebo period, 194 hypertensive (diastolic blood pressure (DBP) 80 mm Hg and systolic blood pressure (SBP) 130 mm Hg) patients with well-controlled type II diabetes were randomized to receive either 8 mg of candesartan once a day (o.d.) or 10 mg olmesartan o.d. and titrated after 1 month to 16 mg candesartan o.d. or 20 mg olmesartan o.d., respectively; the treatment period had a 1-year duration. We evaluated body weight, body mass index, SBP, DBP, glycated hemoglobin, fasting plasma glucose, M value, adiponectin (ADN), resistin (r), retinol-binding protein 4, visfatin, vaspin and high-sensitivity C-reactive protein (Hs-CRP) at their baseline values and after 6 and 12 months of treatment. We observed no variation in body weight or glycemic profile for either treatment. SBP and DBP were significantly reduced by both treatments (from 144±8/886 to 126±5/774 mm Hg by candesartan (P

Original languageEnglish
Pages (from-to)790-795
Number of pages6
JournalHypertension Research
Volume33
Issue number8
DOIs
Publication statusPublished - Aug 2010

Keywords

  • adipokines
  • candesartan
  • olmesartan
  • type II diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients'. Together they form a unique fingerprint.

Cite this